| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Thoracic Surgery and Department V of Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, 13-3, Kamiyamacho, Kitaku, Osaka 530 [M. M., K. N., S-i. I., T. T.], and Department of Pathology and Tumor Biology, Faculty of Medicine, Kyoto University, Kyoto 606 [T. K.], Japan
The application of reliable markers is of major importance for predicting the prognosis of and instituting the appropriate postsurgical treatment of patients with breast cancer. Previously we showed that motility-related protein-1 (MRP-1), which is identical to CD9, regulates cell motility, and that cultured tumor cells transfected with MRP-1/CD9 cDNA have low motility and low metastatic potential. In addition, MRP-1/CD9 immunoblotting and immunohistochemical study with breast cancer revealed that MRP-1/CD9 expression diminished as the clinical stage of a given breast cancer advanced and that the MRP-1/CD9 gene and protein expression in the metastatic lymph nodes was strikingly lower than in the primary breast cancers. In this study, we also investigated the expression of MRP-1/CD9 by immunoblotting and immunohistochemical analysis in 143 freshly resected invasive ductal carcinomas of the breast: 52 tumors were stage I, 61 were stage II, and 30 were stage III. Tumors were classified as MRP-1/CD9 positive when a band intensity of >30% compared with positive control cells, ZR-75-30 were evaluated with the antibody M31-15, and those with intensities <30% as negative. Moreover, these results were ascertained by immunostaining. Tumor specimens classified as MRP-1/CD9 positive using Western blotting had >50% of the cancer cells immunostained with M31-15, and those classified as MRP-1/CD9 reduced had <50% of the cancer cells immunostained with M31-15. There were 97 patients with MRP-1/CD9 positive tumors and 46 patients whose tumors had reduced MRP-1/CD9 levels. The disease-free rate of the former group of patients was strikingly higher than that of the latter (84.7% versus 51.4%, P < 0.001). Similarly, the overall survival rate was also significantly different between the two groups (93.6% versus 69.6%, P = 0.004). Multivariate analysis with the Cox regression model indicated that MRP-1/CD9 positivity correlated better with disease-free survival (P < 0.001) than estrogen receptor, tumor, and lymph node status. Our data suggest that low MRP-1/CD9 expression by tumors of the breast may be associated with poor prognosis. It is conceivable that testing for MRP-1/CD9 may identify node-negative breast cancer patients who are at high risk for early disease recurrence.
1 Supported in part by Grants-in-Aid from the Ministry of Education in Japan and The Sagawa Foundation for Promotion of Cancer Research (M. M.).
2 To whom requests for reprints should be addressed.
Received 12/19/95. Accepted 2/ 6/96.
This article has been cited by other articles:
|
|
 |
|
  Y. Nakazawa, S. Sato, M. Naito, Y. Kato, K. Mishima, H. Arai, T. Tsuruo, and N. Fujita Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis Blood, September 1, 2008; 112(5): 1730 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Wang, L. R. Begin, N. G. Berube, S. Chevalier, A. G. Aprikian, H. Gourdeau, and M. Chevrette Down-Regulation of CD9 Expression during Prostate Carcinoma Progression Is Associated with CD9 mRNA Modifications Clin. Cancer Res., April 15, 2007; 13(8): 2354 - 2361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takeda, N. Hattori, T. Tokuhara, Y. Nishimura, M. Yokoyama, and M. Miyake Adenoviral Transduction of MRP-1/CD9 and KAI1/CD82 Inhibits Lymph Node Metastasis in Orthotopic Lung Cancer Model Cancer Res., February 15, 2007; 67(4): 1744 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. H. Yang, O. V. Kovalenko, T. V. Kolesnikova, M. M. Andzelm, E. Rubinstein, J. L. Strominger, and M. E. Hemler Contrasting Effects of EWI Proteins, Integrins, and Protein Palmitoylation on Cell Surface CD9 Organization J. Biol. Chem., May 5, 2006; 281(18): 12976 - 12985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W M Liu, Y J Cao, Y J Yang, J Li, Z Hu, and E-K Duan Tetraspanin CD9 regulates invasion during mouse embryo implantation J. Mol. Endocrinol., February 1, 2006; 36(1): 121 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gronborg, T. Z. Kristiansen, A. Iwahori, R. Chang, R. Reddy, N. Sato, H. Molina, O. N. Jensen, R. H. Hruban, M. G. Goggins, et al. Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach Mol. Cell. Proteomics, January 1, 2006; 5(1): 157 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cariappa, T. Shoham, H. Liu, S. Levy, C. Boucheix, and S. Pillai The CD9 Tetraspanin Is Not Required for the Development of Peripheral B Cells or for Humoral Immunity J. Immunol., September 1, 2005; 175(5): 2925 - 2930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huang, J. Groth, K. Sossey-Alaoui, L. Hawthorn, S. Beall, and J. Geradts Aberrant Expression of Novel and Previously Described Cell Membrane Markers in Human Breast Cancer Cell Lines and Tumors Clin. Cancer Res., June 15, 2005; 11(12): 4357 - 4364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sauer, J. Windisch, C. Kurzeder, V. Heilmann, R. Kreienberg, and H. Deissler Progression of Cervical Carcinomas Is Associated with Down-Regulation of CD9 But Strong Local Re-expression at Sites of Transendothelial Invasion Clin. Cancer Res., December 15, 2003; 9(17): 6426 - 6431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-R. Kao, J.-Y. Shih, W.-C. Wen, Y.-P. Ko, B.-M. Chen, Y.-L. Chan, Y.-W. Chu, P.-C. Yang, C.-W. Wu, and S. R. Roffler Tumor-associated Antigen L6 and the Invasion of Human Lung Cancer Cells Clin. Cancer Res., July 1, 2003; 9(7): 2807 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Gutierrez-Lopez, S. Ovalle, M. Yanez-Mo, N. Sanchez-Sanchez, E. Rubinstein, N. Olmo, M. A. Lizarbe, F. Sanchez-Madrid, and C. Cabanas A Functionally Relevant Conformational Epitope on the CD9 Tetraspanin Depends on the Association with Activated beta 1 Integrin J. Biol. Chem., January 3, 2003; 278(1): 208 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Longo, M. Yanez-Mo, M. Mittelbrunn, G. de la Rosa, M.-L. Munoz, F. Sanchez-Madrid, and P. Sanchez-Mateos Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells Blood, December 15, 2001; 98(13): 3717 - 3726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tokuhara, H. Hasegawa, N. Hattori, H. Ishida, T. Taki, S. Tachibana, S. Sasaki, and M. Miyake Clinical Significance of CD151 Gene Expression in Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2001; 7(12): 4109 - 4114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nakamura, K. Handa, R. Iwamoto, T. Tsukamoto, M. Takahasi, and E. Mekada Immunohistochemical Distribution of CD9, Heparin Binding Epidermal Growth Factor-like Growth Factor, and Integrin {{alpha}}3{beta}1 in Normal Human Tissues J. Histochem. Cytochem., April 1, 2001; 49(4): 439 - 444. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Shi, H. Fan, L. Shum, and R. Derynck The Tetraspanin CD9 Associates with Transmembrane TGF-{alpha} and Regulates TGF-{alpha}-induced EGF Receptor Activation and Cell Proliferation J. Cell Biol., February 7, 2000; 148(3): 591 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Klein-Soyer, D. O. Azorsa, J.-P. Cazenave, and F. Lanza CD9 Participates in Endothelial Cell Migration During In Vitro Wound Repair Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 360 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-l. Huang, N. Kohno, E. Ogawa, M. Adachi, T. Taki, and M. Miyake Correlation of Reduction in MRP-1/CD9 and KAI1/CD82 Expression with Recurrences in Breast Cancer Patients Am. J. Pathol., September 1, 1998; 153(3): 973 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Kester, B.-j. M. van der Leede, P. T. van der Saag, and B. van der Burg Novel Progesterone Target Genes Identified by an Improved Differential Display Technique Suggest That Progestin-induced Growth Inhibition of Breast Cancer Cells Coincides with Enhancement of Differentiation J. Biol. Chem., June 27, 1997; 272(26): 16637 - 16643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Stipp, T. V. Kolesnikova, and M. E. Hemler EWI-2 Is a Major CD9 and CD81 Partner and Member of a Novel Ig Protein Subfamily J. Biol. Chem., October 26, 2001; 276(44): 40545 - 40554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Woods and J. R. Couchman Integrin Modulation by Lateral Association J. Biol. Chem., August 4, 2000; 275(32): 24233 - 24236. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
